We acknowledge that the limitations of our study are the lack of in vivo preclinical studies analyzing the actions of SST and CORT in the prostate gland physiology under normal and pathological-PCa conditions, the lack of analyzed metastatic CRPC samples in our internal cohort of patients, and that further work will be required to evaluate whether the levels of CORT expression could be used as a predictive molecular biomarker to select patients with PCa, especially CRPC, susceptible to being treated with SSAs. The gene discussed is CORT; the disease is posterior cortical atrophy.